Zhuge Aoxiang, Li Shengjie, Yuan Yin, Li Bo, Li Lanjuan
State Key Laboratory for Diagnosis, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China.
Food Funct. 2021 Oct 19;12(20):10239-10252. doi: 10.1039/d1fo01807h.
() has been widely used in dietary supplements and clinical treatments. Previous studies demonstrated the protective effect of LI01 on liver injury induced by D-galactosamine (D-GaIN) in rats. Accumulating evidence indicates that and are highly coordinated; so in this study, we focus on the synergistic effect of LI01 and TC01 on the alleviation of liver injury caused by D-GaIN in rats and aim to find out the underlying interaction between the two strains. We observed reduced hepatic damage in the D-GaIN-treated rats with probiotic pre-administration, characterized by lower levels of AST and ALT ( < 0.05) and decreased HAI (Histological Activity Index) scores. Moreover, cotreatment with LI01 and TC01 more effectively decreases proinflammatory cytokines TNF-α, MCP-1 and M-CSF ( < 0.05) so as to inhibit systemic inflammation. Gut barrier dysfunction was ameliorated with compound probiotic pretreatment, as evidenced by the ultrastructure integrity, decreased histological score and elevated TJP-1 expression. What's more, supplementation with LI01 and TC01 markedly alleviates gut dysbiosis in the G-DaIN-treated rats, with enrichment of short chain fatty acid (SCFA) producers and group, a decreased / (F/B) ratio and depletion of proinflammatory microbes, such as and . This study highlights the synergistic effect of dietary supplements LI01 and TC01 on the protection against liver failure, which is probably altering gut microbiota.
（）已广泛应用于膳食补充剂和临床治疗中。先前的研究表明LI01对大鼠D-半乳糖胺（D-GaIN）诱导的肝损伤具有保护作用。越来越多的证据表明[具体内容1]和[具体内容2]高度协调；因此在本研究中，我们关注LI01和TC01对减轻大鼠D-GaIN所致肝损伤的协同作用，并旨在找出这两种菌株之间潜在的相互作用。我们观察到益生菌预给药的D-GaIN处理大鼠肝脏损伤减轻，其特征是AST和ALT水平较低（<0.05）以及肝组织活动指数（HAI）评分降低。此外，LI01和TC01联合治疗更有效地降低促炎细胞因子TNF-α、MCP-1和M-CSF（<0.05），从而抑制全身炎症。复合益生菌预处理改善了肠道屏障功能障碍，超微结构完整性、组织学评分降低以及TJP-1表达升高证明了这一点。更重要的是，补充LI01和TC01显著减轻了G-DaIN处理大鼠的肠道微生物群失调，短链脂肪酸（SCFA）产生菌[具体菌群1]和[具体菌群2]富集，/（F/B）比值降低以及促炎微生物如[具体微生物1]和[具体微生物2]减少。本研究强调了膳食补充剂LI01和TC01对预防肝衰竭的协同作用，这可能是通过改变肠道微生物群实现的。
